IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Other languages ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Delayed Hong Kong S.E. Other stock markets 11:07:14 2024-07-17 pm EDT			5-day change	1st Jan Change
12.92 ^HKD	+0.47%		-0.46%	-56.79%

Jul. 03	ImmuneOnco Doses First Patient in Phase 3 Clinical Trial of Hodgkin Lymphoma Drug	MT
Jul. 03	ImmuneOnco Biopharmaceuticals Inc. Announces Updates on the Clinical Trial of IMM01 (Timdarpacept) in Combination with Tislelizumab	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ImmuneOnco Doses First Patient in Phase 3 Clinical Trial of Hodgkin Lymphoma Drug	Jul. 03
ImmuneOnco Biopharmaceuticals Inc. Announces Updates on the Clinical Trial of IMM01 (Timdarpacept) in Combination with Tislelizumab	Jul. 03
ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China	Jun. 24
ImmuneOnco Biopharmaceuticals Inc. Obtains Investigational New Drug Approval for the Phase Ib/III Clinical Trial of IMC-002	Jun. 21
ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	May. 30
ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director	May. 28
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China	May. 17
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	May. 17
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	Apr. 17
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	Mar. 26
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Immuneonco Biopharmaceuticals CFO Resigns	Mar. 03
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes	Mar. 01
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	Nov. 19
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	Nov. 07
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11
Hong Kong Stocks Retreat On Fears Over China Property Default; ImmuneOnco Biopharmaceuticals Gains 5%	23-09-05
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Other languages

Filters